Discounted Cash Flow
Ionis Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $346.6m | $-86.6m | $-119.2m | -25.0% | — |
| 2017 | $507.7m (46.5%) | $-6.0m (93.1%) | $-6.0m (95.0%) | -1.2% (95.3%) | $0.08 |
| 2018 | $599.7m (18.1%) | $273.7m (4685.3%) | $589.3m (9970.7%) | 45.6% (3981.8%) | $2.09 (2512.5%) |
| 2019 | $1.1b (87.2%) | $294.1m (7.5%) | $314.8m (-46.6%) | 26.2% (-42.6%) | $2.12 (1.4%) |
| 2020 | $729.3m (-35.0%) | $-451.3m (-253.4%) | $772.0k (-99.8%) | -61.9% (-336.2%) | $-3.23 (-252.4%) |
| 2021 | $810.5m (11.1%) | $-28.6m (93.7%) | $18.8m (2340.9%) | -3.5% (94.3%) | $-0.20 (93.8%) |
| 2022 | $587.4m (-27.5%) | $-269.7m (-843.2%) | $-290.1m (-1639.4%) | -45.9% (-1201.4%) | $-1.90 (-850.0%) |
| 2023 | $787.6m (34.1%) | $-366.3m (-35.8%) | $-331.3m (-14.2%) | -46.5% (-1.3%) | $-2.56 (-34.7%) |
| 2024 | $705.1m (-10.5%) | $-453.9m (-23.9%) | $-546.2m (-64.9%) | -64.4% (-38.4%) | $-3.04 (-18.8%) |
| 2025 | $943.7m (33.8%) | $-381.4m (16.0%) | $-320.0m (41.4%) | -40.4% (37.2%) | $-2.38 (21.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.